A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles

Lancet Gastroenterol Hepatol. 2025 Jul;10(7):671-684. doi: 10.1016/S2468-1253(25)00069-X. Epub 2025 May 20.

Abstract

The Coaltion for Global Hepatitis Elimination's National Hepatitis Elimination Profiles assess the status of national data, policy, and programme development the elimination of viral hepatitis. Profiles from 33 countries and territories show progress, towards elimination of hepatitis B with 24 (73%) of them meeting the 2025 WHO interim target of 0·5% or less HBsAg prevalence in children younger than 5 years. 22 (67%) of countries and territories profiled have policies for universal hepatitis B birth-dose vaccination of newborns. Access to hepatitis B testing and treatment, including removing HBsAg screening and hepatitis B treatment patient co-payments and simplifying treatment algorithms, remains suboptimal, especially in low-income and middle-income countries and territories. Of the seven profiled countries and territories meeting the 60% WHO 2025 diagnosis coverage target, all but one (Rwanda) is a high-income country or territory. No country or territory has met the WHO 2025 treatment target of at least 50% of people living with hepatitis B receiving treatment. The profiles guide national planning and identify priorities for resource mobilisation to further accelerate hepatitis B elimination.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use
  • Child, Preschool
  • Disease Eradication* / organization & administration
  • Global Health
  • Health Policy*
  • Hepatitis B Surface Antigens / blood
  • Hepatitis B Vaccines / administration & dosage
  • Hepatitis B* / diagnosis
  • Hepatitis B* / drug therapy
  • Hepatitis B* / epidemiology
  • Hepatitis B* / prevention & control
  • Humans
  • Infant, Newborn
  • World Health Organization

Substances

  • Hepatitis B Vaccines
  • Antiviral Agents
  • Hepatitis B Surface Antigens